驱动压限制性通气策略与常规肺保护性通气策略在ARDS/ARF患者中的比较:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入4项RCT共465例ARDS/ARF患者,比较驱动压限制性通气策略与常规肺保护性通气策略。主要终点短期死亡率无显著差异:28天死亡率OR=1.01(95%CI 0.49–2.10,P=0.98,I²=56%),ICU死亡率OR=1.24(95%CI 0.81–1.89,P=0.33,I²=36%),院内死亡率OR=1.21(95%CI 0.79–1.84,P=0.38,I²=0%)。驱动压限制性通气组ICU住院时间缩短(平均差=-2.95天,95%CI -5.17至-0.74,P=0.009,I²=7%),28天内无呼吸机天数(P=0.86)和住院时间(P=0.52)无差异,气压伤(P=0.31)和酸中毒(P=0.43)发生率无显著差异。作者认为现有证据有限,驱动压限制性通气未显示明确优于常规肺保护性通气,需大型RCT确定其临床价值。
要点
- 在ARDS/ARF患者中,驱动压限制性通气与常规肺保护性通气相比,28天死亡率无显著差异(OR=1.01,95%CI 0.49–2.10,P=0.98,I²=56%,4项RCT,465例)。
- ICU死亡率(OR=1.24,95%CI 0.81–1.89,P=0.33,I²=36%,3项RCT,355例)和院内死亡率(OR=1.21,95%CI 0.79–1.84,P=0.38,I²=0%,3项RCT,355例)均无显著差异。
- 驱动压限制性通气组ICU住院时间较常规肺保护性通气组缩短2.95天(平均差=-2.95天,95%CI -5.17至-0.74,P=0.009,I²=7%,4项RCT,465例)。
- 两组28天内无呼吸机天数(P=0.86)和住院时间(P=0.52)无差异,气压伤(P=0.31)和酸中毒(P=0.43)发生率无显著差异。
- 作者认为现有证据有限,驱动压限制性通气未显示明确优于常规肺保护性通气,需大型RCT确定其临床价值、识别反应性临床表型并建立标准化临床应用流程。
适用人群与场景
- 纳入标准:随机对照试验,比较驱动压限制性通气策略与常规肺保护性通气策略,人群为急性呼吸窘迫综合征/急性呼吸衰竭(ARDS/ARF)患者。
研究设计与关键结果
- 研究类型:随机对照试验的系统评价与荟萃分析;共检索到1417条记录,最终纳入4项研究(n=465)符合纳入标准。
- 主要终点短期死亡率:28天死亡率(4项RCT,465例;OR=1.01;95%CI 0.49–2.10;P=0.98;I²=56%)、ICU死亡率(3项RCT,355例;OR=1.24;95%CI 0.81–1.89;P=0.33;I²=36%)、院内死亡率(3项RCT,355例;OR=1.21;95%CI 0.79–1.84;P=0.38;I²=0%)在两组间均无显著差异。
- 驱动压限制性通气与更短的ICU住院时间相关(4项RCT,465例;平均差=-2.95天,95%CI -5.17至-0.74,P=0.009;I²=7%)。
- 两组28天内无呼吸机天数(P=0.86)和住院时间(P=0.52)无差异。
- 两组气压伤发生率(P=0.31)和酸中毒发生率(P=0.43)无显著差异。
- 两组驱动压和潮气量(Vt)相当。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析;研究计划已在PROSPERO注册(注册号CRD420251069853)。
- 局限:作者结论指出基于当前有限证据(limited evidence),驱动压限制性通气未显示明确优于常规肺保护性通气,需大型RCT确定其临床价值、识别反应性临床表型并建立标准化临床应用流程。
对床旁实践的改变
- 作者认为,基于当前有限证据,驱动压限制性通气在ARDS/ARF患者中较常规肺保护性通气无明确获益,无生存获益但ICU住院时间更短,需大型RCT确定其临床价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although driving pressure (DP) has been consistently demonstrated to be an independent predictor of mortality in mechanically ventilated patients, the clinical benefits of DP-limited ventilation strategies compared with conventional lung protective ventilation (CLPV) for patients with acute respiratory distress syndrome/acute respiratory failure (ARDS/ARF) remain controversial. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared DP-limited ventilation strategies with CLPV in patients with ARDS/ARF. The Cochrane Central Register of Controlled Trials, EMBASE, PubMed, Web of Science and Scopus databases were systematically searched from inception to June 2025. The primary outcome was short-term mortality. RESULTS: A total of 1417 records were identified, with 4 studies (n = 465) meeting the inclusion criteria. No significant differences in mortality outcomes, including 28-day mortality (4 RCTs, 465 patients; Odds ratio = 1.01; 95% Confidence interval [0.49, 2.10]; P = 0.98; I2 = 56%), intensive care unit (ICU) mortality (3 RCTs, 355 patients; Odds ratio = 1.24; 95% Confidence interval [0.81, 1.89]; P = 0.33; I2 = 36%), or in-hospital mortality (3 RCTs, 355 patients; Odds ratio = 1.21; 95% Confidence interval [0.79, 1.84]; P = 0.38; I2 = 0%), were observed between the groups. DP-limited ventilation was associated with a shorter length of ICU stay (4 RCTs, 465 patients; Mean difference =-2.95 days, 95% CI [-5.17, -0.74], P = 0.009; I2 = 7%). Analysis revealed no difference in ventilator-free days within 28 days (P = 0.86) and the length of hospital stay (P = 0.52) between the two ventilation strategies. Additionally, no significant difference in the incidence of barotrauma (P = 0.31) or acidosis (P = 0.43) was observed. The DP and tidal volume (Vt) were comparable between the groups. CONCLUSIONS: Based on current limited evidence, DP-limited ventilation showed no clear benefit over CLPV in patients with ARDS/ARF, with no survival benefit and a shorter length of ICU stay, warranting large RCTs to determine its clinical value, identify responsive clinical phenotypes, and establish standardized clinical application procedures. TRIAL REGISTRATION: The research plan was registered at PROSPERO, and the registration number is CRD420251069853.
参考来源
- Cheng J, Ma A, Liang G, et al. Driving pressure-limited ventilation strategies versus conventional lung protective ventilation strategies for patients with ARDS/ARF: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2025. PMID: 41345693. doi:10.1186/s13054-025-05722-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。